2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1737 Transcription factor networks critical for Waldenström's macroglobulinemia cells: Functional characterization and therapeutic implications.

Torsten Steinbrunn, MD, PhD, Zachary R Hunter, PhD2, Shizuka Yamano3, Oliver Bohorquez4, Amanda Kofides, MSc5, Olga Dashevsky, PhD6, Huihui Tang, PhD7, Shirong Liu, PhD8, Maria Luisa Guerrera9, Xia Liu, MD10, Christopher Patterson, MBA, MPH11, Steven Treon, MD, PhD12, Ricardo De Matos Simoes, PhD13, Constantine Mitsiades, MD, PhD14
1 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
2 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States
3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
4 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
5 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States
6 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
7 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
8 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
9 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
10 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States
11 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States
12 Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
13 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
14 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States, Ludwig Center at Harvard Medical School, Boston, MA, United States

Background:

Despite major therapeutic progress, Waldenström's Macroglobulinemia (WM) remains incurable. Developing novel therapies depends on systematic characterization of the molecular vulnerabilities that are essential for WM cell survival. CRISPR-based functional genomic studies have identified biologically and therapeutically relevant dependencies in other neoplasias, including plasma cell malignancies. Many of these dependencies are transcription factors (TFs) or regulators of their function and they often cannot be readily identified through conventional “omics” approaches for molecular profiling of tumor cells. Building on this experience, we therefore applied CRISPR-based functional genomic studies in vitro to identify genes that are essential for survival/proliferation of WM cells and could represent important, yet previously understudied, therapeutic targets for WM.

 Methods:

The current study places emphasis on TFs/transcriptional regulators identified in our genome-scale CRISPR KO screens in 3 WM lines (BCWM1, RPCI-WM1 and MWCL1; Brunello sgRNA library,4 sgRNAs/gene). Candidate TFs were prioritized based on: (i) potent or recurrent depletion of their KOs in the WM lines (e.g., depletion of ≥3 of 4 sgRNAs, with nominal p<0.05 and log2FC<-1.0 [MAGeCK/rank aggregation analyses], in ≥2 of the 3 WM cell lines, or with ranking in the top 20 most essential TFs for ≥1 of these WM lines); (ii) absence of “pan-essentiality” (i.e., hits do not appear as essential genes in similar CRISPR KOs studies for >80-90% of hematologic or solid tumor cell lines); and (iii) recurrent expression in primary WM cells based on publicly available bulk RNA-seq (e.g., average log2TPM>1.0 in WM samples from GSE232994): these criteria intended to identify genes that are preferentially essential for WM lines, relevant for patient-derived WM cells, while excluding genes that are broadly essential for all/most tumor types and may hence be associated with greater on-target toxicities.

 Results:

Genome-scale CRISPR screening identified 60+ known or putative TFs or transcriptional/epigenetic regulators essential for at least one WM line. We confirmed that transcripts for these TFs or regulators are recurrently detectable in primary WM cells using bulk RNA-seq and scRNA-seq studies (e.g., in the publicly available dataset GSE235723). Candidate essential genes identified from this study include TFs with known roles in WM or other plasma cell dyscrasias (e.g., IRF4, IKZF3, IRF2, NFKB2; along with the chromatin regulator EP300), supporting the validity of the screening approach. Several hits also included genes involved in the biology of lymphomas/lymphoid leukemias (e.g., BATF, PAX5, EBF1, etc.), myeloid leukemias (SPI1, ZBTB7A) or hematologic malignancies more broadly (e.g., TFAP4, ZNF217, ZNF687, TRIM28), as well as several TFs with limited or no previous evidence for functional roles in WM or other neoplasias, suggesting potential WM-selective therapeutic vulnerabilities.

Beyond IRF4, several TFs considered its partners/interactors, including BATF, SPI1 (PU.1) and SPIB, were also identified as essential in one or more WM lines, suggesting that this transcriptional module represents a central regulatory hub sustaining WM cell survival. Contrarily to CRISPR studies in MM cells, PAX5 was identified as an essential dependency whereas PRDM1 was not, representing potential distinct features in the lineage-defining transcriptional programs of WM and MM.

With few exceptions (e.g., SPI1), most essential TFs for WM cells were neither recurrently mutated nor overexpressed in WM compared with normal counterparts, consistent with observations in MM and other malignancies that most tumor type preferential dependencies, especially TFs, are often not readily identified from genomic or transcriptomic alterations alone.

 Conclusions:

Our genome-scale CRISPR studies define the TF dependency landscape of WM and indicate that WM cells have both, dependencies shared with MM and B-cell lymphomas, as well as distinct dependencies, including genes that have not been previously linked with WM or most other neoplasias, and may represent preferential therapeutic targets. These findings identify functional therapeutic vulnerabilities beyond conventional “omics” approaches in WM cells.

Torsten Steinbrunn, MD, PhD: Janssen - Other (including travel support)